Copy Number Gains of Chromosome 17 Identified by Dual in Situ Hybridization in Non-small Cell Lung Cancer Tissue Correlate with Overexpression of C-Myc

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2022 Jun 16

PMID 35706805

Authors

Patrapim Sunpaweravong

Patcharaporn Thongwatchara

Rassamee Chotipanvithayakul

Surasak Sangkhathat

Paramee Thongsuksai

Affiliations

Soon will be listed here.

Abstract

Background: c-Myc regulates multiple genes involved in cell proliferation in various cancer types including non-small cell lung cancer (NSCLC). Copy number gains of cytoband 17q25.3, along with chromosome 17, have been reported in NSCLC patients, emphasizing the clinical significance as a potential molecular target for therapy. The upregulation of c-Myc has been found to accelerate tumor development associated with duplication of the syntenic human cytoband 17q25.3. This study aimed to explore and compare the correlations of chromosome 17 copy number and c-Myc expression in NSCLC with the paired-normal respiratory epithelium and to examine their role as potential molecular targets for NSCLC therapy.

Methods: A total of 66 NSCLC tissue samples with paired-normal respiratory epithelium were examined. The copy number of chromosome 17 was determined by human epidermal growth factor receptor 2 ()/centromeric enumeration probe of chromosome 17 (CEP17) dual in situ hybridization (DISH).

Results: Copy number gains of chromosome 17 were identified in 8 of 60 (13.3%) available NSCLC specimens. No copy number gains of chromosome 17 were demonstrated in the paired-normal respiratory epithelium. The mean (1.2±0.3) and CEP17 (1.4±0.3) copy numbers of the normal respiratory epithelium were significantly lower than those of the NSCLC tissue [1.8±1.0 2.0±0.8, respectively (P<0.001)]. Twelve of 66 (18.2%) NSCLC patients had overexpression of c-Myc. Five (41.7%) of the patients whose tumors positive for c-Myc had gene amplification [1] or copy number gain of chromosome 17 [4]. gene amplification or copy number gain of chromosome 17 and high expression of c-Myc were associated with decreased overall survival.

Conclusions: Both biomarkers deserve further investigation to identify NSCLC patients with poorer survival outcomes requiring better therapeutic approaches.

References

Arcila M, Chaft J, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M . Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012; 18(18):4910-8. PMC: 3865806. DOI: 10.1158/1078-0432.CCR-12-0912. View

Mazieres J, Peters S, Lepage B, Cortot A, Barlesi F, Beau-Faller M . Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013; 31(16):1997-2003. DOI: 10.1200/JCO.2012.45.6095. View

McRonald F, Liloglou T, Xinarianos G, Hill L, Rowbottom L, Langan J . Down-regulation of the cytoglobin gene, located on 17q25, in tylosis with oesophageal cancer (TOC): evidence for trans-allele repression. Hum Mol Genet. 2006; 15(8):1271-7. DOI: 10.1093/hmg/ddl042. View

Heinmoller P, Gross C, Beyser K, Schmidtgen C, Maass G, Pedrocchi M . HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin. Clin Cancer Res. 2003; 9(14):5238-43. View

Langan J, Cole C, Huckle E, Byrne S, McRonald F, Rowbottom L . Novel microsatellite markers and single nucleotide polymorphisms refine the tylosis with oesophageal cancer (TOC) minimal region on 17q25 to 42.5 kb: sequencing does not identify the causative gene. Hum Genet. 2004; 114(6):534-40. DOI: 10.1007/s00439-004-1100-3. View

Yu M, Ohira M, Li Y, Niizuma H, Oo M, Zhu Y . High expression of ncRAN, a novel non-coding RNA mapped to chromosome 17q25.1, is associated with poor prognosis in neuroblastoma. Int J Oncol. 2009; 34(4):931-8. DOI: 10.3892/ijo_00000219. View

Suzuki M, Shiraishi K, Yoshida A, Shimada Y, Suzuki K, Asamura H . HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation. Lung Cancer. 2014; 87(1):14-22. DOI: 10.1016/j.lungcan.2014.10.014. View

Ladanyi M, Lui M, Antonescu C, Meindl A, Argani P, Healey J . The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene. 2001; 20(1):48-57. DOI: 10.1038/sj.onc.1204074. View

Risk J, Evans K, Jones J, Langan J, Rowbottom L, McRonald F . Characterization of a 500 kb region on 17q25 and the exclusion of candidate genes as the familial Tylosis Oesophageal Cancer (TOC) locus. Oncogene. 2002; 21(41):6395-402. DOI: 10.1038/sj.onc.1205768. View

10.

Mai S . Initiation of telomere-mediated chromosomal rearrangements in cancer. J Cell Biochem. 2010; 109(6):1095-102. DOI: 10.1002/jcb.22501. View

11.

El-Telbany A, Ma P . Cancer genes in lung cancer: racial disparities: are there any?. Genes Cancer. 2012; 3(7-8):467-80. PMC: 3527990. DOI: 10.1177/1947601912465177. View

12.

Wojnarowicz P, Provencher D, Mes-Masson A, Tonin P . Chromosome 17q25 genes, RHBDF2 and CYGB, in ovarian cancer. Int J Oncol. 2012; 40(6):1865-80. DOI: 10.3892/ijo.2012.1371. View

13.

Wiener F, Schmalter A, Mowat M, Mai S . Duplication of Subcytoband 11E2 of Chromosome 11 Is Regularly Associated with Accelerated Tumor Development in v-abl/myc-Induced Mouse Plasmacytomas. Genes Cancer. 2011; 1(8):847-58. PMC: 3092250. DOI: 10.1177/1947601910382897. View

14.

Gao F, Dabbs D, Cooper K, Bhargava R . Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases. Am J Clin Pathol. 2013; 141(1):102-10. DOI: 10.1309/AJCP6CXS8OSRHXIR. View

15.

Li B, Ross D, Aisner D, Chaft J, Hsu M, Kako S . HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers. J Thorac Oncol. 2016; 11(3):414-9. PMC: 4698879. DOI: 10.1016/j.jtho.2015.10.025. View

16.

Morris C, Haataja L, McDonald M, Gough S, Markie D, Groffen J . The small GTPase RAC3 gene is located within chromosome band 17q25.3 outside and telomeric of a region commonly deleted in breast and ovarian tumours. Cytogenet Cell Genet. 2000; 89(1-2):18-23. DOI: 10.1159/000015583. View

17.

Sunpaweravong P, Thu K, Lam W, Mai S . Assessment of the clinical relevance of 17q25.3 copy number and three-dimensional telomere organization in non-small lung cancer patients. J Cancer Res Clin Oncol. 2015; 142(4):749-56. DOI: 10.1007/s00432-015-2080-5. View

18.

Varella-Garcia M . Chromosomal and genomic changes in lung cancer. Cell Adh Migr. 2010; 4(1):100-6. PMC: 2852566. DOI: 10.4161/cam.4.1.10884. View

19.

. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543-50. PMC: 4231481. DOI: 10.1038/nature13385. View

20.

Uppal S, Aviv H, Patterson F, Cohen S, Benevenia J, Aisner S . Alveolar soft part sarcoma--reciprocal translocation between chromosome 17q25 and Xp11. Report of a case with metastases at presentation and review of the literature. Acta Orthop Belg. 2003; 69(2):182-7. View